Marker Therapeutics, Inc.
MRKR
$1.19
$0.00030.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.28% | -4.38% | 21.60% | 64.04% | 60.18% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.22% | 102.78% | 101.58% | -225.54% | -14,931.81% |
| Change in Net Operating Assets | -114.93% | -29.51% | 27.38% | 174.29% | 144.48% |
| Cash from Operations | 33.64% | 57.92% | 59.47% | 30.27% | 39.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -100.00% | 5,633.95% | 8,332.95% |
| Cash from Investing | -- | -100.00% | -100.00% | 820.66% | 477.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,256.56% | -91.89% | -23.86% | -29.58% | 697.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,256.56% | -91.89% | -23.86% | -35.03% | 446.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.58% | -1,306.51% | -34.05% | 121.96% | 110.50% |